Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update Leadership appointment strengthens strategic and development capabilities. FDA Type D Meeting provides additional guidance

Cadrenal Therapeutics

Reports First-Quarter 2025 Financial

Results and Provides Corporate Update

Leadership appointment

strengthens strategic and development capabilities.

FDA Type D Meeting provides additional guidance

for advancing the clinical development of tecarfarin

Collaboration Agreement with Abbott (NYSE:

ABT) validates the need for new anticoagulation options

PONTE VEDRA, Fla., May

8, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical

company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter

ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin.

"In the first quarter of 2025, Cadrenal

continued to build on the momentum we achieved during 2024," said Quang X. Pham, Chairman & CEO. "The appointment of

James Ferguson, M.D., FACC, FAHA, as our Chief Medical Officer we believe positions us for success in reviewing potential assets to add

to our portfolio and designing and executing our clinical program for tecarfarin. The finalized Collaboration Agreement with Abbott validates

the critical need in the market for a new anticoagulant for patients with left ventricular assist devices (LVADs). And our meeting with

the FDA provided additional guidance in the design of a pivotal trial."

Highlights from the Quarter Ended March 31,

2025, and Other Recent Events:

In February 2025, Cadrenal appointed James J.

Ferguson, M.D., FACC, FAHA, as Chief Medical Officer to lead the review of business development opportunities to expand the Company's

pipeline and drive the late-stage clinical development of tecarfarin for conditions requiring chronic anticoagulation therapy.

In February 2025, Cadrenal met with the U.S.

Food and Drug Administration (FDA) for a Type D meeting. The FDA provided additional guidance on the appropriate design for a Phase 3

tecarfarin trial and welcomed submission of a final study design for review.

Collaboration Agreement with Abbott

In March 2025, we announced a Collaboration Agreement

with Abbott (NYSE: ABT) to support our pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices

(TECH-LVAD) trial. Under the agreement, Abbott will share insights from recent HeartMate 3 clinical trials and will support Cadrenal

with trial design, site identification, trial awareness, and HeartMate 3 expertise.

Operational Milestones

During the quarter, Cadrenal successfully completed

the technical transfer and manufacturing of its tecarfarin drug substance (API) from a CDMO site located in Asia to a CDMO site in the

United States. This initiative was done to support the company's clinical and regulatory development strategy for tecarfarin and

to improve supply chain security.

Cadrenal also conducted strategic market opportunity

research for multiple indications, including patients with left ventricular assist devices. This research indicates that tecarfarin is

uniquely positioned to provide clinical value to patients in the rapidly growing LVAD market, which is projected to nearly double by

2032. This research also showed that tecarfarin has the potential to provide clinical benefit in additional high-need cardiovascular,

renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients.

Participation in Key Investor, Medical, and

Business Development Conferences

Cadrenal was active during the first quarter

in several significant conferences to build corporate visibility and underscore its commitment to advancing innovation in anticoagulation

therapy. Investor interactions included participation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco,

a Company presentation at the BIO CEO and Investor Conference in New York, and, after the close of the quarter, a Company presentation

at the Centri Capital Conference at Nasdaq headquarters in New York. Shortly after the quarter's close, Cadrenal participated in the

18th National Conference on Anticoagulation Therapy in Washington, D.C.

Strategic Development Collaborations

Cadrenal continues to explore opportunities to

add to the Company's clinical pipeline and collaborate with potential development partners to advance the development of tecarfarin

for patients with LVADs and for other indications requiring chronic anticoagulation.

First Quarter 2025 Financial Highlights

Research and development expenses for the quarter

ended March 31, 2025, were $1.7 million compared to $0.6 million for the same period in 2024. General and administrative expenses for

the quarter ended March 31, 2025, were $2.3 million compared to $1.1 million for the same period in 2024. Cadrenal reported a net loss

of $3.8 million for the quarter ending March 31, 2025, compared to $1.7 million for the same period in 2024.

On March 31, 2025, Cadrenal had cash and cash

equivalents of $7.3 million, compared to $10.0 million as of December 31, 2024. The Company had approximately 1.9 million shares of common

stock outstanding as of March 31, 2025.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a biopharmaceutical

company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin,

a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant

(blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.

Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have

significant serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation

therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable

Cadrenal is pursuing a pipeline-in-a-product

approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical

circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status

for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).

Cadrenal is opportunistically pursuing business

development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit https://www.cadrenal.com/

and connect with us on LinkedIn.

Any statements in this press release about future

expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking

statements." The words "anticipate," "believe," "continue," "could," "estimate,"

"expect," "intend," "may," "plan," "potentially," "predict,"

"project," "should," "target," "will," "would" and similar expressions are

intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements

include statements regarding the The the appointment of James Ferguson, M.D., FACC, FAHA, as the Company's Chief Medical Officer

positioning the Company for success in reviewing potential assets to add to its portfolio and designing and executing its clinical program

for tecarfarin; the finalized Collaboration Agreement with Abbott validating the critical need in the market for a new anticoagulant

for patients with left ventricular assist devices (LVADs); Abbott sharing insights from recent HeartMate 3 clinical trials and

supporting Cadrenal with trial design, site identification, trial awareness, and HeartMate 3 expertise; the LVAD market projected

to nearly double by 2032; and tecarfarin having the potential to provide clinical benefit in additional high-need cardiovascular, renal,

and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients Actual results may differ

materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to

utilize Abbott's expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal

clinical trial for tecarfarin in LVAD patients by Cadrenal; for tecarfarin to provide clinical benefit in additional high-need cardiovascular,

renal, and mechanical heart valve indications, reinforcing tecarfarin's potential value proposition for patients; the ability of

Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the

Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the

Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form

8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal

securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new

information, future events, or otherwise.